RT Journal Article
SR Electronic
T1 A new era in the management of pulmonary arterial hypertension related to scleroderma: endothelin receptor antagonism
JF Annals of the Rheumatic Diseases
JO Ann Rheum Dis
FD BMJ Publishing Group Ltd and European League Against Rheumatism
SP 1009
OP 1014
DO 10.1136/ard.2003.017673
VO 63
IS 9
A1 Hachulla, E
A1 Coghlan, J G
YR 2004
UL http://ard.bmj.com/content/63/9/1009.abstract
AB Evidence suggests that endothelin may have a fundamental role in scleroderma pathogenesis, including pulmonary arterial hypertension (PAH)—a leading cause of death in patients with scleroderma. Development of a new class of drug, endothelin receptor antagonists, heralds an improved outlook for patients with scleroderma and related diseases. Heightened vigilance towards early detection of PAH in scleroderma and a multidisciplinary approach to diagnosis and treatment may improve clinical outcomes for these patients.